- Atara Biotherapeutics press release (NASDAQ:ATRA): Q2 GAAP EPS of $0.18 beats by $1.14.
- Revenue of $51.58M (+1232.8% Y/Y) beats by $45.05M.
Atara to Focus on R&D Activities Prioritizing Upcoming Milestones for Key Pipeline Assets
ATA188 Phase 2 EMBOLD Study Interim Analysis Completed with Target Enrollment Achieved; Primary Endpoint Data Read Out Planned for October 2023
FDA Recommended Pathway to Potential Tab-cel BLA Filing Without Need for New Clinical Trial; European Commission Approval on Track for Q4 2022
ATA3219 on Track for Q4 2022 IND Submission.